文献速递乳腺MR乳腺X线US

特异性对高危乳腺癌磁共振、钼靶和超声筛查成本效果的影响

Impact of specificity on cost-effectiveness of screening women at high risk of breast cancer with magnetic resonance imaging, mammography and ultrasound.
PubMed 文献 · Eur J Radiol · 2021-01-30

本研究采用决策分析和马尔可夫模型,从美国医疗系统视角比较高危乳腺癌女性筛查中磁共振乳腺成像(MRM)与常规成像的成本效果,时间跨度30年。基础分析显示,钼靶(XM)总成本36201.57美元、累积效果19.53 QALYs,MRM总成本39050.97美元、累积效果19.59 QALYs,MRM的增量成本效果比(ICER)为45373.94美元/QALY。敏感性分析显示,只要MRM特异性不低于86.7%,MRM仍为成本效果策略。

要点

  • 高危乳腺癌每年筛查时,MRM的ICER为45373.94美元/QALY。
  • MRM特异性不低于86.7%时,MRM仍具成本效果。
  • US及XM+US的ICER值高于支付意愿阈值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Aim of this study was to analyze the comparative cost-effectiveness of MR-mammography vs conventional imaging in a screening setting for women with high risk of breast cancer, with particular focus on the impact of specificity of MRM.

METHOD: Decision analytic modelling and Markov Modelling were applied to evaluate cumulative costs of each screening modality and their subsequent treatments as well as cumulative outcomes in quality adjusted life years (QALYs). For the selected time horizon of 30 years, false positive and false negative results were included. Model input parameters for women with high risk of breast cancer were estimated based on published data from a US healthcare system perspective. Major influence factors were identified and evaluated in a deterministic sensitivity analysis. Based on current recommendations for economic evaluations, a probabilistic sensitivity analysis was conducted to test the model stability.

RESULTS: In a base-case analysis, screening with XM vs. MRM and treatment resulted in overall costs of $36,201.57 vs. $39,050.97 and a cumulative effectiveness of 19.53 QALYs vs. 19.59 QALYs. This led to an incremental cost-effectiveness ratio (ICER) of $ 45,373.94 per QALY for MRM. US and XM + US resulted in ICER values higher than the willingness to pay (WTP). In the sensitivity analyses, MRM remained a cost-effective strategy for screening high-risk patients as long as the specificity of MRM did not drop below 86.7 %.

CONCLUSION: In high-risk breast cancer patients, MRM can be regarded as a cost-effective alternative to XM in a yearly screening setting. Specificity may be an important cost driver in settings with yearly screening intervals.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Kaiser CG, Dietzel M, Vag T, et al. Impact of specificity on cost-effectiveness of screening women at high risk of breast cancer with magnetic resonance imaging, mammography and ultrasound. Eur J Radiol. 2021. PMID: 33556759. doi:10.1016/j.ejrad.2021.109576

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。